Grimes & Company, Inc. Adma Biologics, Inc. Call Options Transaction History
Grimes & Company, Inc.
- $3.66 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ADMA
# of Institutions
319Shares Held
185MCall Options Held
917KPut Options Held
91.6K-
Black Rock Inc. New York, NY18.6MShares$407 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.1MShares$395 Million0.01% of portfolio
-
State Street Corp Boston, MA13MShares$284 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA12.6MShares$275 Million0.05% of portfolio
-
Morgan Stanley New York, NY8.6MShares$188 Million0.01% of portfolio
About ADMA BIOLOGICS, INC.
- Ticker ADMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 196,356,992
- Market Cap $4.28B
- Description
- ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...